10x GenomicsTXG +2.85%62 Days Payable is 30.81 as of Mar. 2026, which is 44% below its 10-year median of 55.36. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $19.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 606 Healthcare Providers & Services companies, 10x Genomics ranks worse than 76.24% on this metric.
The historical rank and industry rank for 10x Genomics's Days Payable or its related term are showing as below:
TXG'
s Days Payable Range Over the Past 10 Years
Min: 23.52 Med: 55.36 Max: 188.13
Current: 27.91
During the past 9 years, 10x Genomics's highest Days Payable was 188.13. The lowest was 23.52. And the median was 55.36.
TXG's Days Payable is ranked worse than 76.24% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs TXG: 27.91
10x Genomics's Days Payable
increased
from Mar. 2025 (21.20) to Mar. 2026 (30.81).
It may suggest that 10x Genomicsdelayed paying its suppliers.
10x Genomics Days Payable Related Terms
10x Genomics Days Payable Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Days Payable distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
10x Genomics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Days Payable of 30.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 10x Genomics and its competitors. This is 44% below median its historical median of 55.36. Over the past decade, 10x Genomics' Days Payable has ranged from 23.52 to 188.13. According to the industry distribution chart, 10x Genomics ranks #462 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 76.2%.
Is 10x Genomics' Days Payable too high?
10x Genomics' current Days Payable of 30.81 is 44% below median its 10-year median of 55.36. Over the past 10 years, this metric has ranged from a low of 23.52 to a high of 188.13. The Healthcare Providers & Services industry median Days Payable is 58.21. 10x Genomics' value of 30.81 is 47.1% below this industry median. Based on the distribution chart, 10x Genomics ranks #462 out of 606 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Days Payable compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #462 out of 606 companies for Days Payable. This places 10x Genomics in the lower half of its industry. The industry median Days Payable is 58.21. 10x Genomics' value of 30.81 is 47.1% below this benchmark. Historically, 10x Genomics' own Days Payable has ranged from 23.52 to 188.13 over the past decade. While the company's 10-year median is 55.36 vs. the industry median of 58.21, 10x Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Days Payable of 30.81 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Days Payable is 30.81, which is 44% below median its own 10-year median of 55.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.00, compared to a current price of $36.70 — trading 93.2% above its estimated fair value. The current Days Payable is 30.81, which is 44% below median its 10-year median of 55.36 and 47.1% below the Healthcare Providers & Services industry median of 58.21. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For 10x Genomics (TXG), the current Days Payable is 30.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $36.70 is trading 93.2% above its estimated GF Value™ of $19.00.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Days Payable: 30.81 (44% below median its 10-year median of 55.36)
GF Value™: $19.00 vs. price of $36.70 (93.2% above fair value)
Industry Position: 47.1% below the Healthcare Providers & Services median (#462 of 606)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
